The development of, and globlal access to, effective antiretroviral medications revolutionized HIV-1 care. In addition to their important life-saving treatment benefits, antiretrovirals have recently been demonstrated to be highly efficacious for HIV-1 prevention as well, when used as antiretroviral therapy (ART) to reduce the infectiousness of HIV-1 infected persons and pre-exposure prophylaxis (PrEP) for uninfected persons who have ongoing HIV-1 exposure. Antiretroviral-based prevention, both ART and PrEP, are among the most promising strategies for reducing the number of new HIV-1 infections globally. Consequently, policymakers are weighing the costs, benefits, and risks of public health implementation of ART and PrEP for HIV-1 prevention. One potential risk of both ART and PrEP is the selection and transmission of HIV-1 variants that are resistant to one or more antiretroviral medications, which can result in HIV-1 treatment failure with associated morbidity and mortality and increased costs (of more complex second-and third-line treatment regimens); thus, there has been considerable speculation about the potential risks of resistance from both ART and PrEP.
In this issue of the Journal, Abbas et al. present a mathematical model to estimate the number of HIV-1 infections averted and the number of acquired and transmitted HIV-1 cases of resistance in a setting similar to South Africa and under several scenarios about coverage of ART and PrEP [1] . For PrEP, the authors assumed use of combination emtricitabine-tenofovir, for which efficacy has been demonstrated [2] [3] [4] . For ART, the authors modeled first-line regimens containing the same antiretrovirals and assumed that second-line drugs were not available, given limited availability of second-line medications in many resource-limited settings. Not surprisingly, the results of this mathematical modeling article underscore that population-level coverage and effectiveness (which is dependent on adherence) are the main determinants of the number of infections averted with both ART and PrEP and that implementation of a combination of ART and PrEP prevents more infections in a population than a program that delivers exclusively either ART or PrEP. More interestingly, the model analysis also suggests that HIV-1 drug resistance in a population would be largely driven by ART, not PrEP, in all scenarios modeled, as a result of insufficient ART adherence or lack of viral load monitoring in ART programs, leading to selection of resistant variants during incomplete viral suppression. The model also finds that the population prevalence of resistance directly as a result of PrEP may be very low and that the greatest resistance risks related to PrEP would be from inappropriate use by persons already HIV-1 infected, rather than from PrEP being prescribed for HIV-1 prevention, even anticipating inadvertent prescribing for persons with unrecognized acute HIV-1 infection.
What do these findings mean for potential implementation of PrEP for HIV-1 prevention?
First, these results directly address the often-voiced concern that PrEP will lead to substantial For ART, the key benefit that was not included in this model was its health-impact in terms of saving lives. As the primary benefit of ART is to prolong life, and the primary problem of resistance is the loss of efficacy of ART, this is an important gap in the model. For PrEP, a critical operational factor for maximizing impact in terms of infections averted will be 'prioritization', in which age, gender and risk behaviors are incorporated into risk assessments for potential PrEP users to maximize the likelihood that PrEP is provided to those most at risk of HIV-1 infection. To optimally use resources for PrEP, programs will need to prioritize those who are at highest risk of HIV-1 acquisition and are motivated to take PrEP. Whereas the authors of For both PrEP and ART for HIV-1 prevention, adherence is key to effectiveness. For ART, the result is adherence over a lifetime, or until a cure is available. Expanding implementation of ART for HIV-1 prevention will include persons initiating at higher CD4 counts and earlier in their disease course before they have experienced symptoms, and they may face heightened adherence challenges. PrEP adherence has different challenges than ART, namely requiring persons without HIV-1 to perceive their own risk sufficiently to initiate and adhere to PrEP. Thus, PrEP needs to be delivered in a different model than ART, as it is not a commitment to life-long medications, but specially directed to individuals during life periods of highest risk. 
